Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 5/20 | 0.32 |
| ▸ | CTSK | P43235 | 5/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811424 | 0.83 | FOLH1 (0.41) | KMT2AMEN1GAACA1CA2 | |
| SCHEMBL6624311 | 0.82 | CA1 (0.34) | KMT2AMEN1GAACA1CA2 | |
| SCHEMBL1662092 | 0.81 | KMT2A (0.38) | KMT2AMEN1GAACA1CA2 | |
| SCHEMBL1662090 | 0.81 | KMT2A (0.38) | KMT2AMEN1GAACA1CA2 | |
| SCHEMBL5943155 | 0.76 | CPB2 (0.39) | KMT2AMEN1GAACA1CA2 | |
| SCHEMBL28086823 | 0.75 | KMT2A (0.39) | KMT2AMEN1GAACA1CA2 | |
| SCHEMBL330114 | 0.72 | LTA4H (0.36) | KMT2AMEN1GAAPGDNOS1 | |
| SCHEMBL2611908 | 0.72 | LTA4H (0.36) | KMT2AMEN1GAAPGDNOS1 | |
| SCHEMBL375959 | 0.72 | LTA4H (0.36) | KMT2AMEN1GAAPGDNOS1 | |
| SCHEMBL29943608 | 0.71 | TDP1 (0.44) | KMT2AMEN1GAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080063701-A1 | Vector | IV VEC LIMITED (GB) | 2008-03-13 | — | — | US | disclosed |
| EP-1814594-A2 | VECTOR COMPRISING POLYMER MODIFIED SIRNA LIPOSOMES | IC Vec Limited (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006016097-A2 | VECTOR COMPRISING POLYMER MODIFIED SIRNA LIPOSOMES | IC VEC LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080063701-A1 | Vector | LPCAT1, HDLBP, AGO2 | KMT2A 1171/4885MEN1 1670/4885GAA 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.